Tofacitinib Treatment in Patients With Active COVID-19 Infection

    September 2021 in “ Curēus ”
    Abdulmajeed Alajlan, Lama Alzamil, Amal M Aseri
    From the encyclopedia
    Tofacitinib →

    a JAK inhibitor for alopecia areata and other autoimmune conditions

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Image
    Studysummary In this study, two patients with alopecia universalis continued using tofacitinib during active COVID-19 infection and showed no worsening of their illness, despite potential concerns about immunosuppression.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The document discusses the use of tofacitinib, a JAK1 and JAK3 inhibitor, in treating alopecia areata, an autoimmune disorder causing hair loss. Tofacitinib has been shown to be effective in promoting hair regrowth in patients with this condition. Despite concerns about potential immunosuppression during active COVID-19 infections, the document reports on two cases where patients with alopecia universalis continued their tofacitinib treatment without experiencing any worsening of their COVID-19 symptoms. This suggests that tofacitinib may be safely used without adverse effects on the course of COVID-19, although the sample size is very small with only two cases.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results